Expert Group Recommendations: It is advised to assess alterations in the PIK3CA, AKT1, and PTEN genes in patients with HR‐positive advanced breast cancer who experience disease progression following endocrine therapy. This evidence concerns the gene PTEN and breast carcinoma.